What do systematic reviews say?

Physical activity advice plus omega 3 vs no physical activity advice plus omega 3

The review found no eligible studies for this question.

• Interventions for fatigue in inflammatory bowel disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Electroacupuncture vs no treatment

• Interventions for fatigue in inflammatory bowel disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 34 participants
  Low

Medicine‐separated moxibustion combined with acupuncture vs wheat bran‐separated moxibustion combined with shallow acupuncture

• Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 102 participants
  Very low

Web‐based education vs standard book‐based education

• Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Very low

Relaxation vs WAIT LIST

The review found no eligible studies for this question.

• Interventions for the management of abdominal pain in ulcerative colitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Stellate ganglion block vs sulphasalazine

The review found no eligible studies for this question.

• Interventions for the management of abdominal pain in ulcerative colitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Opioids vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for painful sickle cell vaso‐occlusive crises in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Opioids vs active comparators

The review found no eligible studies for this question.

• Pharmacological interventions for painful sickle cell vaso‐occlusive crises in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Mesalamine vs placebo

Mesalamine showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).

• Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
  RR 5.92 [0.7, 49.9]
  1 study · 62 participants
  Low

Budesonide vs placebo

It is very uncertain whether budesonide changes withdrawals due to adverse events compared with placebo (very low certainty).

• Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
  RR 0.97 [0.43, 2.17]
  5 studies · 290 participants
  Very low

Boswellia serrata vs placebo

Boswellia serrata extract showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).

• Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
  RR 2.82 [0.12, 64.39]
  1 study · 31 participants
  Low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Budesonide showed no clear difference in withdrawals due to adverse events compared with mesalazine (low certainty).

• Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
  RR 0.09 [0.01, 1.65]
  1 study · 55 participants
  Low

NSAIDs vs placebo

• Pharmacological interventions for painful sickle cell vaso‐occlusive crises in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 93 participants
  Very low

Physical activity advice plus placebo vs no physical activity advice plus placebo

The review found no eligible studies for this question.

• Interventions for fatigue in inflammatory bowel disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Physical activity advice plus placebo vs no physical activity advice plus omega 3

The review found no eligible studies for this question.

• Interventions for fatigue in inflammatory bowel disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Topical capsaicin vs placebo

• Pharmacological interventions for pain in patients with temporomandibular disorders 2010 · Cochrane All outcomes

  4 weeks
  Three participants from the topical capsaicin group withdrew from the study by Winocur et al 2000 due to the severity of the burning sensation and redness.
  1 study · 30 participants
  GRADE not reported

Oral gabapentin vs placebo

• Pharmacological interventions for pain in patients with temporomandibular disorders 2010 · Cochrane All outcomes

  12 weeks
  Four of the participants withdrew from the study by Kimos et al 2007 due to adverse effects, but neither the type of adverse effect nor the trial group was specified.
  1 study · 44 participants
  GRADE not reported

Oral glucosamine hydrochloride/chondroitin sulphate vs placebo

• Pharmacological interventions for pain in patients with temporomandibular disorders 2010 · Cochrane All outcomes

  3 months
  Two allergic reactions and one severe abdominal pain led to three withdrawals from the intervention group in the study by Nguyen et al 2001.
  1 study · 45 participants
  GRADE not reported

Oral clonazepam (benzodiazepine) vs placebo

• Pharmacological interventions for pain in patients with temporomandibular disorders 2010 · Cochrane All outcomes

  60 days
  One participant in the clonazepam group withdrew from the study by Harkins et al 1991 due to severe headache.
  1 study · 20 participants
  GRADE not reported

Monthly pegloticase vs placebo

Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).

• Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
  RR 8.19 [1.12, 59.71]
  1 study · 127 participants
  Moderate